Dr. Marcus Butler

Co-leader, Immuno-oncology Translational Research Initiative (ACTION)

Dr. Marcus Butler is the Clinical Co-Leader of OICR’s Immuno-oncology Translational Research Initiative. His expertise includes clinical trials in a variety of immune therapies including adoptive T-cell therapy and checkpoint blockade.

Dr. Butler is the Clinical Head of the Immune Monitoring Team at the Princess Margaret Cancer Centre, where his group performs a wide variety of immunologic assays to examine the impact of therapies on immune phenotype and function.

Before joining the Princess Margaret Cancer Centre, he was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute.

Current affiliations

Co-Leader, Immuno-oncology Translational Research Initiative
Medical Oncology Disease Site Lead for Melanoma/Skin Oncology, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto
Associate Member, Department of Immunology, University of Toronto

Research interests

Melanoma
Skin cancer
Adoptive cell therapy
Immunotherapy
Gene engineered T cell therapy
Tumor infiltrating lymphocyte therapy

Top publications

Nguyen LT, Saibil SD, Sotov V, …, Butler MO. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother. 2019; 68:773-785.
Kagoya Y, Nakatsugawa M, Yamashita Y, …, Butler MO, …, Hirano N. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016; 126(9):3479-94.
Nakatsugawa M, Rahman MA, Yamashita Y, …, Butler MO, Hirano N. CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells. Sci Rep. 2016; 6:23821.
Nakatsugawa M, Yamashita Y, Ochi T, …, Butler MO, Hirano N. Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol. 2015; 194(7):3487-500.
Butler MO, Friedlander P, Milstein MI, …, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011; 3(80):80ra34.

See Dr. Butler’s recent publications on PubMed or Google Scholar.

Previous experience and education

Medical Oncology Fellowship, Dana-Farber/Partners CancerCare
Internal Medicine Residency, Johns Hopkins Hospital
MD, Yale University School of Medicine
BA, Rice University

Opportunities to collaborate

For opportunities to collaborate with Dr. Butler, please contact him directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

Contact

Dr. Marcus Butler
Marcus.Butler@uhn.ca

Back to the top